Lead Compound: Evexomostat (SDX-7320)

Targeting a Neglected Patient Population

We’re developing our lead compound evexomostat (SDX-7320) to address the well-established link between cancer and dysregulated metabolic hormones.
Our initial target patient population — 2nd line metastatic HR+/Her2- breast cancer with the PIK3CA mutation in combination with drugs from the PI3K/Akt inhibitor class and SERDs — is estimated at over 30,000 new patients per year in the United States and EU 4+1.
Phase 1 results show that evexomostat (SDX-7320) can significantly improve insulin sensitivity that have been shown to lead to treatment resistance for drugs from the PI3K inhibitor class.

Many hormones (e.g., leptin, insulin, estrogen) and inflammatory cytokines (e.g., IL6, TNF-α) are known to promote cancer progression. SDX-7320 acts at the physiological level to systemically decrease the levels of these hormones and cytokines while also targeting the tumor microenvironment (angiogenesis).

Evexomostat (SDX-7320) may also stimulate weight loss, which is associated with significant reductions in leptin and insulin, in obese mice (SDX internal data). The corresponding improvements in insulin resistance and in other elements of systemic metabolic dysfunction have been shown to inhibit tumor growth and metastasis in experimental models of breast cancer and melanoma (SDX data).

Furthermore, in preclinical models, evexomostat (SDX-7320) had a superior safety profile and enhanced efficacy at lower doses than other fumagillin-class MetAP2 inhibitors and with reduced dosing frequency.

*BYL-719 is the original name for Piqray/alpelisib

Clinical Programs

SynDevRx is developing evexomostat (SDX-7320) initially for the treatment of postmenopausal women with HR+,Her2-, metastatic breast cancer with the PIK3CA mutation who have progressed following initial therapy with a CKD4/6 inhibitor.
In a recently completed Phase 1 study in late-stage solid tumor cancer patients, evexomostat (SDX-7320) showed significant reductions in fasting insulin and leptin, for cancer patients that had baseline elevated levels (resistance), plus significant increases in the hormone adiponectin.
Additionally, the pro-angiogenic growth factors bFGF (aka FGF2), and VEGF-C were reduced in the Phase 1 study.
The Phase 1 study was a dose escalation safety study in unselected solid tumors. The primary endpoint was to determine the dose and schedule for future clinical studies.
Clinical trials in other indications where metabolic dysfunction is thought to promote the progression of tumors are in the works.